Eli Lilly (LLY.N): It expects to incur $2.8 billion in pre-tax charges in the second quarter of 2026 due to acquisition-related R&D projects, equivalent to an impact of $3.02 per share.

2026-07-09

Eli Lilly (LLY.N): It expects to incur $2.8 billion in pre-tax charges in the second quarter of 2026 due to acquisition-related R&D projects, equivalent to an impact of $3.02 per share.